Slinda (drospirenone) / Insud Pharma - LARVOL DELTA

Effect of oral Drospirenone on clinical and/or biochemical hyperandrogenism in polycystic ovarian syndrome: A pilot study (ISGE 2026) - "This is the first to show that 6 months of treatment with the drospirenone-only contraceptive pill is associated with a reduction in both clinical and biochemical hyperandrogenism. The results support future studies to determine what role it can play as part of the treatment options in PCOS."

Clinical • Acne Vulgaris • Polycystic Ovary Syndrome

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females (clinicaltrials.gov) - P3 | N=1542 | Completed | Sponsor: Insud Pharma | Active, not recruiting ➔ Completed | N=1009 ➔ 1542

Enrollment change • Trial completion

TAEDIUMVITAE: Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis (clinicaltrials.gov) - P=N/A | N=138 | Active, not recruiting | Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

New trial • Endometriosis • Gynecology • Women's Health

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females (clinicaltrials.gov) - P3 | N=1009 | Active, not recruiting | Sponsor: Insud Pharma | Trial primary completion date: May 2024 ➔ Aug 2024

Trial primary completion date

Contraception updates for adolescents. (PubMed, Curr Opin Pediatr) - "Updated evidence-based guidelines and several new contraceptive options should empower providers to provide patient-centered contraception counseling to patients with a variety of health conditions and contraceptive preferences."

Journal • Infectious Disease • Long-acting Reversible Contraceptives • Novel Coronavirus Disease • Pain

Slynd: does a drospirenone progestogen-only pill offer an advantage? (PubMed, Drug Ther Bull) - No abstract available

Journal • Review

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females (clinicaltrials.gov) - P3 | N=1009 | Active, not recruiting | Sponsor: Insud Pharma

Trial completion date • Trial primary completion date

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females (clinicaltrials.gov) - P3 | N=1009 | Active, not recruiting | Sponsor: Insud Pharma | Recruiting ➔ Active, not recruiting

Enrollment closed

Contraception: Past, present, and future (Contemporary OB/GYN) - "In a recent interview, Michael L. Krychman, MD...discussed changes in the contraceptive landscape - from progesterone-only pills to intrauterine devices (IUDs)....Krychman: The most important thing to remember is to listen to your patients. When they come in, they have preconceived ideas about what is best for them. I think part of what we do as health care professionals is educate our patients, and we need to educate them on all the options."

Interview

Efficacy, Safety, and Tolerability of LPRI-CF113 as Oral Contraceptive in Females (clinicaltrials.gov) - P3 | N=1009 | Recruiting | Sponsor: Insud Pharma | Not yet recruiting ➔ Recruiting

Enrollment open